Login Create Account

Powerpack

Unlock full stockrow access for only $7.9/month and boost yourself as an investor.

  • Watchlist

    Keep track of companies that you follow and research.

  • 10 Years of Data

    Full access to our data with predictions and indicators that we calculate daily.

  • Screener

    Full access to our screener with tons of custom values and customizable email notifications.

  • XLS Exports

    Excel export of financials and screeners you define and save.

Subscribe now
Screener Weekly Summary

Coherus Oncology, Inc. CHRS

Healthcare  —  Biotechnology
Overview Business Profile Analyst Commentary Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K
Quarterly (Descending) Quarterly (Ascending) Annual (Descending) Annual (Ascending) TTM (Descending) TTM (Ascending)

Financial statements are limited to most recent four years or quarters for non-powerpack users

Ten years worth of data (where available), most important trends and XLS exports are available for our Powerpack users.

Register an account and get your Powerpack now or Login

An Income Statement, also known as a Profit and Loss Statement, summarizes a company's revenues, expenses, and profits over a specific period. It highlights how revenue is transformed into net income, showcasing operational efficiency. Key components include total revenue, cost of goods sold (COGS), gross profit, operating expenses, and net profit. Businesses use the Income Statement to assess financial performance, make strategic decisions, and ensure profitability. Investors and stakeholders analyze it to gauge the company’s financial health and future growth potential.

Dec '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 Dec '19 Dec '18 Dec '17 Dec '16
Revenue 42.17 26.39 257.24 211.04 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
Revenue Growth 59.81% (89.74%) 21.89% (35.37%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — ‡‡‡‡‡ ‡‡‡‡‡
Cost of Revenue 13.81 8.73 158.99 70.08 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — —
Gross Profit 28.36 17.66 98.25 140.96 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
R&D Expenses 108.89 91.83 109.44 199.36 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
SG&A Expenses 100.60 125.48 192.02 198.48 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Operating Income (181.13) (199.65) (203.20) (256.88) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Interest Expense (Operating) — — — 32.47 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Non-operating Income/Expense (1.99) (15.74) (35.07) (34.87) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Non-operating Interest Expenses 9.00 10.73 40.54 32.47 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EBT (183.12) (215.39) (238.27) (291.75) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Income Tax Provision 0.00 0.00 (0.38) 0.00 ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ — — —
Income after Tax (183.12) (215.39) (237.89) (291.75) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Dividends (Preferred) — — — — — — — ‡‡‡ — ‡‡‡
Non-Controlling Interest — — — — — — — ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Income Common 168.02 28.51 (237.89) (291.75) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EPS (Basic) 1.43 0.25 (2.53) (3.76) ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EPS (Diluted) 1.43 0.25 (2.53) (3.76) ‡‡‡‡‡ ‡‡‡‡ ‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares (Basic, Weighted) 117.14 114.55 94.16 77.63 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Shares (Diluted, Weighted) 117.14 114.55 94.16 77.63 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Gross Margin 67.24% 66.93% 38.19% 66.79% ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡ ‡‡‡
EBIT Margin (429.51%) (756.58%) (78.99%) (121.72%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EBT margin (434.23%) (816.23%) (92.62%) (138.24%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Net Profit Margin 398.43% 108.03% (92.48%) (138.24%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Free Cash Flow Margin (328.45%) (77.46%) (68.09%) (115.22%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EBITDA (177.21) (194.38) (199.41) (253.18) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EBIT (181.13) (199.65) (203.20) (256.88) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Income from Continuous Operations (183.12) (215.39) (237.89) (291.75) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Income from Discontinued Operations 351.15 243.90 — — — — — — — —
Consolidated Net Income/Loss 168.02 28.51 (237.89) (291.75) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EPS (Basic, from Continuous Ops) (1.56) (1.88) (2.53) (3.76) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EPS (Basic, from Discontinued Ops) 3.00 2.13 — — — — — — — —
EPS (Basic, Consolidated) 1.43 0.25 (2.53) (3.76) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EPS (Diluted, from Cont. Ops) (1.56) (1.88) (2.53) (3.76) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EPS (Diluted, from Disc. Ops) 0.00 0.00 — — — — — — — —
Shares (Diluted, Average) 117.14 114.83 94.16 77.63 ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EPS (Diluted, Consolidated) 1.43 0.25 (2.53) (3.76) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
EBITDA Margin (420.21%) (736.58%) (77.52%) (119.97%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡
Operating Cash Flow Margin (328.45%) (77.46%) (67.98%) (114.25%) ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡ ‡‡‡ ‡‡‡‡‡ ‡‡‡‡‡